Precision Medicine Approaches for Cancer Therapy Recent and Advance

Year : 2025 | Volume : 14 | Issue : 01 | Page : 1 11
    By

    Mohd. Wasiullah,

  • Piyush Yadav,

  • Girijesh Yadav,

  • Preeti Yadav,

  1. Principal, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India
  2. Academic Head, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India
  3. Lecturer, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India
  4. Scholor, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India

Abstract

Recent advances in biotechnology have made it possible to identify intricate and distinctive biological characteristics linked to carcinogenesis. Proteomic and RNA studies, immunological markers, tumor and cell-free DNA profiling, and other methods are utilized to find these traits in order to optimize anticancer treatment for specific patients. In recent years, the focus of clinical trials has shifted considerably to enhance treatment outcomes in cancer therapy. Rather than being primarily centered on tumor type, trials are increasingly designed to be gene-directed and histology-agnostic. This approach allows for a more personalized treatment strategy that is tailored to the genetic and molecular profile of the tumor rather than its anatomical location. Additionally, clinical trial designs have embraced innovative and adaptive methodologies, particularly those that integrate biomarker profiling to identify patients who are most likely to benefit from specific treatments. A growing body of evidence from precision medicine trials supports the effectiveness of this approach. These trials have consistently demonstrated that therapies matched to the molecular characteristics of the tumor are associated with improved patient outcomes, including higher response rates and extended progression-free survival, compared to non-matched therapies. This paradigm shift marks a significant advancement in oncology, providing hope for more effective, individualized treatments for a variety of cancers.

Keywords: ctDNA, personalized, precision, molecular profile, matched therapy, genomic landscape

[This article belongs to Research and Reviews: Journal of Oncology and Hematology ]

How to cite this article:
Mohd. Wasiullah, Piyush Yadav, Girijesh Yadav, Preeti Yadav. Precision Medicine Approaches for Cancer Therapy Recent and Advance. Research and Reviews: Journal of Oncology and Hematology. 2025; 14(01):1-11.
How to cite this URL:
Mohd. Wasiullah, Piyush Yadav, Girijesh Yadav, Preeti Yadav. Precision Medicine Approaches for Cancer Therapy Recent and Advance. Research and Reviews: Journal of Oncology and Hematology. 2025; 14(01):1-11. Available from: https://journals.stmjournals.com/rrjooh/article=2025/view=199410


References

  1. Mardis ER, Berger MF. The growing clinical use of genetics in cancer treatment. Nat Rev Clin Oncol. 2018;15(6):353–65.
  2. Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017;168(4):670–91.
  3. Soverini S, Mancini M, Bavaro L, Cavo M, Martinelli G. Chronic myeloid leukemia: The paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer. 2018;17(1):49.
  4. Ignatiadis M, Sotiriou C. Luminal breast cancer: From biology to treatment. Nat Rev Clin Oncol. 2013;10(9):494–506.
  5. Ahn MJ, Wang J, Yang JCH, Lu Y, Atagi S, Mok TS, et al. Overall survival and biomarker analysis of gefitinib plus chemotherapy vs. chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS). J Clin Oncol. 2017;35(34):4027–34.
  6. Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381(7):626–36.
  7. Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018;554(7691):189–94.
  8. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91.
  9. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.
  10. Kimmelman J, Tannock I. The paradox of precision medicine. Nat Rev Clin Oncol. 2018;15(6):341–2.
  11. Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, et al. Proteogenomics connects somatic mutations to signaling in breast cancer. Nature. 2016;534(7605):55–62.
  12. Merlino G, Fiascarelli A, Bigioni M, Bressan A, Irrissuto C, Pellacani A, et al. MEN1611, a novel α-selective PI3K inhibitor in solid tumors. Tumor Biol. 2018;78:2160.
  13. Lin CC, Arkenau HT, Lu S, Sachdev J, Carpeño JDC, Mita M, et al. A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumors and lymphomas. Br J Cancer. 2019;121(2):131–8.
  14. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.
  15. Märkl B, Hirschbühl K, Dhillon C. NTRK-fusions—a new kid on the block. Pathol Res Pract. 2019;215(11):1525.
  16. Polasek TM, Shakib S, Rostami-Hodjegan A. Precision dosing in clinical medicine: Present and future. Expert Rev Clin Pharmacol. 2018;11(8):743–46.
  17. Birkbak NJ, McGranahan N. Cancer genome evolutionary trajectories in metastasis. Cancer Cell. 2019;37(1):8–19.
  18. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, et al. Personalized medicine in a phase I clinical trials program: The MD Anderson Cancer Center initiative. Clin Cancer Res. 2012;18(22):6373–83.
  19. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24.
  20. Van De Haar J, Hoes L, Voest E. Advancing molecular tumor boards: Highly needed to maximize the impact of precision medicine. ESMO Open. 2019;4(2):e000516.
  21. Morgan G, Ward R, Barton M. The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin Oncol (R Coll Radiol). 2004;16(8):549–60.
  22. Williams SC. News feature: Capturing cancer’s complexity. Proc Natl Acad Sci U S A. 2015;112(15):4509–11.
  23. Maciejko L, Smalley M, Goldman A. Cancer immunotherapy and personalized medicine: Emerging technologies and biomarker-based approaches. J Mol Biomark Diagn. 2017;8(1):1–3.
  24. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–11.
  25. Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–6.
Regular Issue Subscription Review Article
Volume 14
Issue 01
Received 14/12/2024
Accepted 23/12/2024
Published 18/02/2025
Publication Time 66 Days
156

Login


My IP

PlumX Metrics